Treatment of hemiplegic migraine with triptans.

Abstract

The objective of this study was to investigate the efficacy, safety and tolerability of triptans in patients who suffer from familial or sporadic hemiplegic migraine. Seventy-six subjects had used triptans at least once as an abortive treatment. Average triptan response was 6.9 (SD +/-3.1) and adverse event severity 4.9 (SD +/-3.3) on a scale from 0 to 10 (no response or side effect 0, excellent response or unbearable side effects 10). None of the patients had an ischaemic stroke or a heart attack. One patient reported prolonged neurological symptoms, related to a single dose of rizatriptan, but there were no pathological findings in several MRI-scans. Triptans seem to be safe and effective treatment for most hemiplegic migraine patients.

• Authors: V Artto, M Nissilä, M Wessman, A Palotie, M Färkkilä, M Kallela
• Journal: European journal of neurology (Eur J Neurol) Vol. 14 Issue 9 Pg. 1053-6 (Sep 2007) ISSN: 1468-1331 [Electronic] England
• PMID: 17718700 (Publication Type: Evaluation Study, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• Serotonin Receptor Agonists
• Tryptamines

Topics

• Adult
• Female
• Humans
• Male
• Middle Aged
• Migraine with Aura (drug therapy)
• Neurologic Examination
• Serotonin Receptor Agonists (therapeutic use)
• Tryptamines (therapeutic use)